Latest news
January 29, 2019
Challenge pour la Qualité de vie du patient 2019 : l’appel à projets est ouvert !
January 7, 2019
Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America
October 11, 2018
Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…
September 28, 2018
The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2018 JCA-Mauvernay Award
July 24, 2018
Debiopharm Investment, BNP Paribas Développement, Bpifrance et Tikehau Capital accompagnent la croissance du groupe Carbonex
May 8, 2018
FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…